PFIZER INC

NYSE: PFE (Pfizer, Inc.)

Kemas kini terakhir: 2 hari lalu, 3:28PM

22.97

-1.32 (-5.43%)

  • 1H -5.43%
  • 5H -8.89%
  • 1B -12.46%
  • 6B -21.34%
  • Tahun Ke Tarikh -13.68%
  • 1T -13.58%
  • 5T -29.97%
Penutupan Terdahulu 24.29
Buka 23.94
Jumlah Dagangan 70,464,566
Purata Dagangan (3B) 45,943,613
Modal Pasaran 130,273,206,272
Harga / Pendapatan (P/E TTM) 16.29
Harga / Pendapatan (P/E Ke hadapan) 8.35
Harga / Jualan (P/S) 2.06
Harga / Buku (P/B) 1.48
Julat 52 Minggu
22.95 (-0%) — 31.54 (37%)
Tarikh Pendapatan 29 Apr 2025
Hasil Dividen (DY TTM) 7.36%
Margin Keuntungan 12.62%
Margin Operasi (TTM) 15.90%
EPS Cair (TTM) 1.41
Pertumbuhan Hasil Suku Tahunan (YOY) 21.90%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -98.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 76.18%
Nisbah Semasa (MRQ) 1.17
Aliran Tunai Operasi (OCF TTM) 12.74 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 12.78 B
Pulangan Atas Aset (ROA TTM) 4.64%
Pulangan Atas Ekuiti (ROE TTM) 9.06%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok Pfizer, Inc. Menurun Menurun

AISkor Stockmoo

0.9
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga 3.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.5
Purata 0.88

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
PFE 130 B 7.36% 16.29 1.48
JNJ 369 B 3.24% 26.47 5.39
ABBV 367 B 3.03% 87.24 109.22
BMY 122 B 4.03% - 7.42
GSK 70 B 4.54% 23.00 4.47
LLY 663 B 0.73% 62.88 52.04

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.06%
% Dimiliki oleh Institusi 67.48%
68.6068.6057.8057.8047.0047.0036.2036.2025.4025.40Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
22.95 (-0%) — 31.54 (37%)
Julat Harga Sasaran
29.00 (26%) — 33.00 (43%)
Tinggi 33.00 (Guggenheim, 43.67%) Beli
Median 29.00 (26.25%)
Rendah 29.00 (UBS, 26.25%) Pegang
29.00 (Citigroup, 26.25%) Pegang
Purata 30.33 (32.04%)
Jumlah 1 Beli, 2 Pegang
Harga Purata @ Panggilan 26.49
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Guggenheim 10 Feb 2025 33.00 (43.67%) Beli 25.87
Citigroup 28 Jan 2025 29.00 (26.25%) Pegang 26.75
UBS 08 Jan 2025 29.00 (26.25%) Pegang 26.86

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
01 Apr 2025 Pengumuman European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
31 Mar 2025 CNBC Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
18 Mar 2025 Pengumuman Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
11 Mar 2025 Pengumuman Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
24 Feb 2025 Pengumuman Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
24 Feb 2025 Pengumuman Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
24 Feb 2025 Pengumuman Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
21 Feb 2025 CNBC Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
13 Feb 2025 Pengumuman Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
12 Feb 2025 Pengumuman U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
10 Feb 2025 CNBC Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
10 Feb 2025 Pengumuman Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
06 Feb 2025 CNBC Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
04 Feb 2025 CNBC Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay off
04 Feb 2025 CNBC Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary 
04 Feb 2025 Pengumuman Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
03 Feb 2025 Pengumuman Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
28 Jan 2025 Pengumuman Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
27 Jan 2025 CNBC Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
27 Jan 2025 Pengumuman Telescope Innovations Presents Results of First Fiscal Quarter 2025
25 Jan 2025 Pengumuman Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
10 Jan 2025 Pengumuman Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
06 Jan 2025 Pengumuman Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Papar semua
Hasil Dividen (DY TTM) 7.36%
Purata Hasil Dividen 5T 4.38%
Nisbah Pembayaran 119.15%
Jangkaan Pembayaran Dividen Seterusnya Sep 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
24 Jan 2025 12 Dec 2024 07 Mar 2025 0.43 Tunai
08 Nov 2024 09 Oct 2024 02 Dec 2024 0.42 Tunai
26 Jul 2024 26 Jun 2024 03 Sep 2024 0.42 Tunai
09 May 2024 24 Apr 2024 14 Jun 2024 0.42 Tunai
25 Jan 2024 14 Dec 2023 01 Mar 2024 0.42 Tunai
09 Nov 2023 04 Oct 2023 04 Dec 2023 0.41 Tunai
27 Jul 2023 22 Jun 2023 05 Sep 2023 0.41 Tunai
11 May 2023 26 Apr 2023 09 Jun 2023 0.41 Tunai
26 Jan 2023 09 Dec 2022 03 Mar 2023 0.41 Tunai
03 Nov 2022 22 Sep 2022 05 Dec 2022 0.4 Tunai
28 Jul 2022 23 Jun 2022 06 Sep 2022 0.4 Tunai
12 May 2022 28 Apr 2022 10 Jun 2022 0.4 Tunai
27 Jan 2022 10 Dec 2021 04 Mar 2022 0.4 Tunai
04 Nov 2021 23 Sep 2021 06 Dec 2021 0.39 Tunai
29 Jul 2021 24 Jun 2021 07 Sep 2021 0.39 Tunai
06 May 2021 22 Apr 2021 04 Jun 2021 0.39 Tunai
28 Jan 2021 11 Dec 2020 05 Mar 2021 0.39 Tunai
05 Nov 2020 24 Sep 2020 01 Dec 2020 0.38 Tunai
30 Jul 2020 25 Jun 2020 01 Sep 2020 0.38 Tunai
07 May 2020 23 Apr 2020 05 Jun 2020 0.38 Tunai
30 Jan 2020 16 Dec 2019 06 Mar 2020 0.38 Tunai
07 Nov 2019 24 Sep 2019 02 Dec 2019 0.36 Tunai
01 Aug 2019 28 Jun 2019 03 Sep 2019 0.36 Tunai
09 May 2019 26 Apr 2019 07 Jun 2019 0.36 Tunai
31 Jan 2019 15 Dec 2018 01 Mar 2019 0.36 Tunai
08 Nov 2018 28 Sep 2018 03 Dec 2018 0.34 Tunai
02 Aug 2018 29 Jun 2018 04 Sep 2018 0.34 Tunai
10 May 2018 26 Apr 2018 01 Jun 2018 0.34 Tunai
01 Feb 2018 18 Dec 2017 01 Mar 2018 0.34 Tunai
09 Nov 2017 27 Sep 2017 01 Dec 2017 0.32 Tunai
02 Aug 2017 22 Jun 2017 01 Sep 2017 0.32 Tunai
10 May 2017 27 Apr 2017 01 Jun 2017 0.32 Tunai
01 Feb 2017 12 Dec 2016 01 Mar 2017 0.32 Tunai
08 Nov 2016 22 Sep 2016 01 Dec 2016 0.3 Tunai
03 Aug 2016 23 Jun 2016 01 Sep 2016 0.3 Tunai
11 May 2016 28 Apr 2016 01 Jun 2016 0.3 Tunai
03 Feb 2016 14 Dec 2015 02 Mar 2016 0.3 Tunai
04 Nov 2015 25 Sep 2015 01 Dec 2015 0.28 Tunai
05 Aug 2015 25 Jun 2015 02 Sep 2015 0.28 Tunai
06 May 2015 23 Apr 2015 02 Jun 2015 0.28 Tunai
04 Feb 2015 14 Dec 2014 03 Mar 2015 0.28 Tunai
05 Nov 2014 23 Oct 2014 02 Dec 2014 0.26 Tunai
30 Jul 2014 26 Jun 2014 03 Sep 2014 0.26 Tunai
07 May 2014 24 Apr 2014 03 Jun 2014 0.26 Tunai
05 Feb 2014 16 Dec 2013 04 Mar 2014 0.26 Tunai
06 Nov 2013 24 Oct 2013 03 Dec 2013 0.24 Tunai
31 Jul 2013 27 Jun 2013 04 Sep 2013 0.24 Tunai
08 May 2013 25 Apr 2013 04 Jun 2013 0.24 Tunai
30 Jan 2013 17 Dec 2012 05 Mar 2013 0.24 Tunai
07 Nov 2012 25 Oct 2012 04 Dec 2012 0.22 Tunai
01 Aug 2012 28 Jun 2012 05 Sep 2012 0.22 Tunai
09 May 2012 26 Apr 2012 05 Jun 2012 0.22 Tunai
01 Feb 2012 12 Dec 2011 06 Mar 2012 0.22 Tunai
08 Nov 2011 27 Oct 2011 06 Dec 2011 0.2 Tunai
03 Aug 2011 23 Jun 2011 06 Sep 2011 0.2 Tunai
11 May 2011 28 Apr 2011 07 Jun 2011 0.2 Tunai
02 Feb 2011 13 Dec 2010 01 Mar 2011 0.2 Tunai
04 Nov 2010 28 Oct 2010 01 Dec 2010 0.18 Tunai
04 Aug 2010 24 Jun 2010 01 Sep 2010 0.18 Tunai
05 May 2010 22 Apr 2010 01 Jun 2010 0.18 Tunai
03 Feb 2010 14 Dec 2009 02 Mar 2010 0.18 Tunai
04 Nov 2009 22 Oct 2009 01 Dec 2009 0.16 Tunai
05 Aug 2009 25 Jun 2009 02 Sep 2009 0.16 Tunai
06 May 2009 23 Apr 2009 02 Jun 2009 0.16 Tunai
04 Feb 2009 15 Dec 2008 03 Mar 2009 0.32 Tunai
05 Nov 2008 23 Oct 2008 02 Dec 2008 0.32 Tunai
06 Aug 2008 26 Jun 2008 03 Sep 2008 0.32 Tunai
07 May 2008 24 Apr 2008 03 Jun 2008 0.32 Tunai
06 Feb 2008 17 Dec 2007 04 Mar 2008 0.32 Tunai
07 Nov 2007 25 Oct 2007 04 Dec 2007 0.29 Tunai
08 Aug 2007 28 Jun 2007 05 Sep 2007 0.29 Tunai
09 May 2007 26 Apr 2007 05 Jun 2007 0.29 Tunai
07 Feb 2007 18 Dec 2006 06 Mar 2007 0.29 Tunai
08 Nov 2006 26 Oct 2006 05 Dec 2006 0.24 Tunai
09 Aug 2006 22 Jun 2006 05 Sep 2006 0.24 Tunai
10 May 2006 27 Apr 2006 06 Jun 2006 0.24 Tunai
08 Feb 2006 12 Dec 2005 07 Mar 2006 0.24 Tunai
08 Nov 2005 27 Oct 2005 06 Dec 2005 0.19 Tunai
10 Aug 2005 23 Jun 2005 06 Sep 2005 0.19 Tunai
11 May 2005 28 Apr 2005 07 Jun 2005 0.19 Tunai
09 Feb 2005 13 Dec 2004 08 Mar 2005 0.19 Tunai
09 Nov 2004 28 Oct 2004 03 Dec 2004 0.17 Tunai
11 Aug 2004 24 Jun 2004 03 Sep 2004 0.17 Tunai
12 May 2004 22 Apr 2004 04 Jun 2004 0.17 Tunai
11 Feb 2004 15 Dec 2003 05 Mar 2004 0.17 Tunai
12 Nov 2003 23 Oct 2003 04 Dec 2003 0.15 Tunai
13 Aug 2003 26 Jun 2003 04 Sep 2003 0.15 Tunai
14 May 2003 24 Apr 2003 05 Jun 2003 0.15 Tunai
15 Jan 2003 16 Dec 2002 14 Feb 2003 0.15 Tunai
13 Nov 2002 24 Oct 2002 05 Dec 2002 0.13 Tunai
14 Aug 2002 27 Jun 2002 05 Sep 2002 0.13 Tunai
15 May 2002 25 Apr 2002 06 Jun 2002 0.13 Tunai
13 Feb 2002 18 Dec 2001 07 Mar 2002 0.13 Tunai
14 Nov 2001 25 Oct 2001 06 Dec 2001 0.11 Tunai
15 Aug 2001 28 Jun 2001 06 Sep 2001 0.11 Tunai
16 May 2001 26 Apr 2001 07 Jun 2001 0.11 Tunai
14 Feb 2001 18 Dec 2000 08 Mar 2001 0.11 Tunai
15 Nov 2000 26 Oct 2000 07 Dec 2000 0.09 Tunai
16 Aug 2000 22 Jun 2000 07 Sep 2000 0.09 Tunai
16 Aug 2000 01 Jun 2000 15 Sep 2000 0.09 Tunai
09 May 2000 27 Apr 2000 08 Jun 2000 0.09 Tunai
16 Feb 2000 13 Dec 1999 09 Mar 2000 0.09 Tunai
09 Nov 1999 28 Oct 1999 09 Dec 1999 0.08 Tunai
04 Aug 1999 24 Jun 1999 09 Sep 1999 0.08 Tunai
05 May 1999 22 Apr 1999 10 Jun 1999 0.22 Tunai
10 Feb 1999 14 Dec 1998 11 Mar 1999 0.22 Tunai
04 Nov 1998 22 Oct 1998 10 Dec 1998 0.19 Tunai
05 Aug 1998 25 Jun 1998 10 Sep 1998 0.19 Tunai
06 May 1998 23 Apr 1998 11 Jun 1998 0.19 Tunai
04 Feb 1998 22 Jan 1998 12 Mar 1998 0.19 Tunai
05 Nov 1997 23 Oct 1997 11 Dec 1997 0.17 Tunai
30 Jul 1997 26 Jun 1997 11 Sep 1997 0.17 Tunai
07 May 1997 24 Apr 1997 12 Jun 1997 0.34 Tunai
05 Feb 1997 23 Jan 1997 13 Mar 1997 0.34 Tunai
06 Nov 1996 24 Oct 1996 12 Dec 1996 0.3 Tunai
31 Jul 1996 27 Jun 1996 12 Sep 1996 0.3 Tunai
08 May 1996 25 Apr 1996 13 Jun 1996 0.3 Tunai
07 Feb 1996 25 Jan 1996 14 Mar 1996 0.3 Tunai
08 Nov 1995 26 Oct 1995 21 Dec 1995 0.26 Tunai
02 Aug 1995 22 Jun 1995 21 Sep 1995 0.26 Tunai
08 May 1995 27 Apr 1995 15 Jun 1995 0.52 Tunai
06 Feb 1995 26 Jan 1995 16 Mar 1995 0.52 Tunai
04 Nov 1994 27 Oct 1994 15 Dec 1994 0.47 Tunai
01 Aug 1994 23 Jun 1994 15 Sep 1994 0.47 Tunai
09 May 1994 28 Apr 1994 16 Jun 1994 0.47 Tunai
07 Feb 1994 27 Jan 1994 17 Mar 1994 0.47 Tunai
05 Nov 1993 28 Oct 1993 16 Dec 1993 0.42 Tunai
02 Aug 1993 25 Jun 1993 16 Sep 1993 0.42 Tunai
10 May 1993 22 Apr 1993 17 Jun 1993 0.42 Tunai
08 Feb 1993 28 Jan 1993 18 Mar 1993 0.42 Tunai
16 Nov 1992 22 Oct 1992 17 Dec 1992 0.37 Tunai
03 Aug 1992 25 Jun 1992 17 Sep 1992 0.37 Tunai
11 May 1992 23 Apr 1992 18 Jun 1992 0.37 Tunai
03 Feb 1992 23 Jan 1992 19 Mar 1992 0.37 Tunai
08 Nov 1991 24 Oct 1991 19 Dec 1991 0.33 Tunai
01 Aug 1991 27 Jun 1991 19 Sep 1991 0.33 Tunai
13 May 1991 25 Apr 1991 20 Jun 1991 0.33 Tunai
22 Feb 1991 24 Jan 1991 21 Mar 1991 0.66 Tunai
09 Nov 1990 25 Oct 1990 20 Dec 1990 0.6 Tunai
06 Aug 1990 28 Jun 1990 20 Sep 1990 0.6 Tunai
14 May 1990 26 Apr 1990 21 Jun 1990 0.6 Tunai
05 Feb 1990 25 Jan 1990 22 Mar 1990 0.6 Tunai
13 Nov 1989 26 Oct 1989 21 Dec 1989 0.55 Tunai
24 Jul 1989 22 Jun 1989 21 Sep 1989 0.55 Tunai
15 May 1989 27 Apr 1989 21 Jun 1989 0.55 Tunai
23 Jan 1989 19 Dec 1988 22 Mar 1989 0.55 Tunai
15 Nov 1988 27 Oct 1988 20 Dec 1988 0.5 Tunai
25 Jul 1988 23 Jun 1988 20 Sep 1988 0.5 Tunai
16 May 1988 28 Apr 1988 20 Jun 1988 0.5 Tunai
12 Feb 1988 28 Jan 1988 21 Mar 1988 0.5 Tunai
16 Nov 1987 22 Oct 1987 21 Dec 1987 0.45 Tunai
27 Jul 1987 25 Jun 1987 21 Sep 1987 0.45 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.430 1 1.87
2024 1.68 4 6.33
2023 1.64 4 5.70
2022 1.60 4 3.12
2021 1.56 4 2.64
2020 1.52 4 4.13
2019 1.44 4 3.87
2018 1.36 4 3.28
2017 1.28 4 3.73
2016 1.20 4 3.89
2015 1.12 4 3.66
2014 1.04 4 3.52
2013 0.960 4 3.30
2012 0.880 4 3.70
2011 0.800 4 3.90
2010 0.720 4 4.33
2009 0.800 4 4.64
2008 1.28 4 7.62
2007 1.16 4 5.38
2006 0.960 4 3.91
2005 0.760 4 3.44
2004 0.680 4 2.67
2003 0.600 4 1.79
2002 0.520 4 1.79
2001 0.440 4 1.16
2000 0.450 5 1.03
1999 0.600 4 1.95
1998 0.760 4 1.92
1997 1.02 4 4.33
1996 1.20 4 9.14
1995 1.56 4 15.66
1994 1.88 4 30.78
1993 1.68 4 30.80
1992 1.48 4 25.82
1991 1.65 4 24.84
1990 2.40 4 75.18
1989 2.20 4 80.07
1988 2.00 4 87.23
1987 0.900 2 48.83
Papar semua
26.5026.5025.2125.2123.9223.9222.6322.6321.3421.34Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.2000.200-0.000-0.000-0.200-0.200-0.400-0.400-0.600-0.600MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda